Investigational drug · Phase 2
IDE397
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for MTAP-null Non-Small-Cell Lung Cancer, MTAP-null Solid Tumors.
Phase 2Last checked: Nov 19, 2026Latest source record: Apr 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
3
Any phase or sponsor naming "IDE397"
First trial start
2023
Aug 1, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "IDE397", any sponsor or status.
Conditions studied
As listed on its trial records.
- MTAP-null Non-Small-Cell Lung Cancer
- MTAP-null Solid Tumors
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "IDE397" as an intervention, largest first.
IDEAYA BiosciencesIndustry
NCT07277413 · 260 participants (planned) · Start Mar 4, 2026 · Primary completion Apr 30, 2028
Drug: IDE892; IDE397 · For: NSCLC Adenocarcinoma; Gastroesophageal Cancer (GC); Gastric Adenocarcinoma and 10 more
Sites: Goodyear, Arizona; Phoenix, Arizona; Duarte, California · 26 sites in all
- Study of IDE397 in Participants With Solid Tumors Harboring MTAP DeletionActive, not recruiting
IDEAYA BiosciencesIndustry
NCT04794699 · 169 participants · Start Apr 14, 2021 · Primary completion Jan 7, 2027
Drug: IDE397; Sacituzumab govitecan · For: Solid Tumor
Sites: Scottsdale, Arizona; Little Rock, Arkansas; Duarte, California · 37 sites in all
AmgenAmgen (AMGN)
NCT05975073 · 53 participants · Start Aug 1, 2023 · Primary completion Feb 25, 2026
Drug: Anvumetostat; IDE397 · For: MTAP-null Non-Small-Cell Lung Cancer; MTAP-null Solid Tumors
Sites: Duarte, California; Denver, Colorado; Indianapolis, Indiana · 27 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- MTAP Deletion in Oncogenesis: A Synthetic Lethality Scenario.
Rodon J, Johnson ML, George B, et al. · Cancer Res 2026
- Targeting the methionine-methionine adenosyl transferase 2A- S -adenosyl methionine axis for cancer therapy.
Guo J, Yang Y, Buettner R, et al. · Curr Opin Oncol 2022
Also in development for MTAP-null Non-Small-Cell Lung Cancer
- AnvumetostatAMG 193Phase 23 trials
Amgen · Advanced MTAP-null Solid Tumors, MTAP-deleted NSCLC, MTAP-null Non-Small-Cell Lung Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Amgen.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.